In this podcast, Contributing Editor Professor Paul Moss has a conversation with Professor Johnny Mahlangu. They discuss Dr. Moss's Diffusion article from the November/December 2018 issue of The Hematologist. The article titled, "Mimicry Not Replacement: Molecular Engineering Transforms the Outlook in Hemophilia A," covers the HAVEN3 study, which focuses on the activity of prophylactic emicizumab in patients with hemophilia who do not have inhibitors. You can find his Diffusion article online at www.hematology.org/Thehematologist/Diffusion/9049.aspx.

Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/